# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Evan Seigerman maintains Eli Lilly and Co (NYSE:LLY) with a Outperform and maintains $1001 price target.
The treatment is intended for adults in the early symptomatic stages of Alzheimer's disease.
On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in p...
American leaders push for lower drug prices, highlighting recent legislation and widespread support for affordable medications....
- Reuters
- Reuters